News Daily News Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes Michael O'Riordan December 08, 2023
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Conference News AHA 2023 Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients Caitlin E. Cox November 07, 2023
Presentation TCT 2023 Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid Presenter: Karol Watson October 26, 2023
News Daily News Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals Yael L. Maxwell October 19, 2023
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Conference News ADA 2023 Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention Michael O'Riordan June 28, 2023
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News ACC 2023 Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study Todd Neale March 10, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Daily News Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3 Michael O'Riordan January 16, 2023